Mosaic TP53 pathogenic variants on multi-gene hereditary cancer panel testing: Clinical characteristics and follow-up testing.

Authors

null

Sarah A. Jackson

GeneDx, Inc., Gaithersburg, MD

Sarah A. Jackson , Maegan Roberts , Jessica L. Mester , Megan L. Marshall , Kristen J. Vogel Postula , Amy R. Stettner , Kevin J. Arvai , Rachel T. Klein , Andrew F. Wagner , Kathleen S. Hruska

Organizations

GeneDx, Inc., Gaithersburg, MD, Northwestern University, Feinberg School of Medicine, Chicago, IL

Research Funding

Other

Background: Li-Fraumeni Syndrome (LFS) is an autosomal dominant cancer susceptibility syndrome due to germline pathogenic variants in TP53 and is associated with a significant risk for sarcomas, female breast, and other cancers. A subset of individuals undergoing germline TP53 analysis will have a variant with an allele fraction (AF) less than that in heterozygous individuals, consistent with mosaicism. TP53 mosaicism may be limited to hematopoietic cells, such as in age-related hematopoietic expansion, or may be constitutional, in which case the variant exists in additional tissues and may increase LFS-associated cancer risks. This study aims to characterize the clinical characteristics and follow-up results of cases with a TP53 mosaic pathogenic or likely pathogenic variant (PV). Methods: We performed a retrospective review of all individuals undergoing multi-gene hereditary cancer panel testing at our diagnostic laboratory. Cases included those with mosaicism for one or more TP53 PV, characterized as an AF of < 35.0% on next-generation sequencing (NGS) on a blood or oral rinse specimen. Data were analyzed utilizing descriptive statistics and hypothesis tests, including Fisher?s exact test. Results: We identified 117 TP53 mosaic PV cases. Among 37 cases that had one or more relatives undergo testing for the mosaic PV, no relatives were positive. Among 21 cases that underwent subsequent fibroblast (FB) testing, 19.0% (4/21) correlated with the initial mosaic result, suggesting constitutional mosaicism. Of those that confirmed on FB, the mean AF for the original sample was 28.3% (n = 4; SD = 3.2%), whereas the mean for those negative on FB was 18.5% (n = 17; SD = 6.3%). Confirmation of mosaicism on FB was associated with an initial NGS AF ≥25.0% (p = 0.0276; FB Pos: 3/4, FB Neg: 2/17) and with a personal history of a breast cancer or sarcoma diagnosed < 46 years (p = 0.0276; FB Pos: 3/4, FB Neg: 2/17). Conclusions: Although NGS is not purely quantitative, apparent constitutional mosaicism appears to correlate with higher AF on NGS. In addition, phenotypes of cases with TP53 mosaicism confirmed via FB are more suggestive of LFS. Further studies are required to establish clinical correlation.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Cancer Prevention, Hereditary Genetics, and Epidemiology

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Germline Genetic Testing

Citation

J Clin Oncol 36, 2018 (suppl; abstr 1580)

DOI

10.1200/JCO.2018.36.15_suppl.1580

Abstract #

1580

Poster Bd #

151

Abstract Disclosures

Similar Abstracts

First Author: Elissa B. Dodd-Eaton

Abstract

2024 ASCO Annual Meeting

Profile of breast cancer in patients with Li-Fraumeni syndrome: An institutional experience.

First Author: Nithin S G

First Author: Bita Nehoray